Interferon β(1a)

C. Pozzilli, T. Koudriavtseva

Research output: Contribution to journalArticlepeer-review


An improved understanding of the immunopathogenesis of multiple sclerosis (MS) has led to therapeutic attempts using immunoregulatory agents in patients with MS, including interferon β. IFN-β(1a) has been tested in relapsing-remitting MS and its effectiveness in reducing exacerbation rate and in slowing sustained worsening of disability after 2 years has been shown. Magnetic resonance imaging results supported the clinical findings, showing a significant reduction in Gd-enhancing lesion frequency and new lesion formation on T2-weighted images. This type of interferon is well tolerated and most adverse events are mild and transient. Further trials are in progress to amplify and clarify the observed benefits of IFN-β(1a).

Original languageEnglish
Pages (from-to)481-493
Number of pages13
JournalBailliere"s clinical neurology
Issue number3
Publication statusPublished - 1997


  • Interferon β(1a)
  • Magnetic resonance imaging
  • Relapsing-remitting multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Interferon β(1a)'. Together they form a unique fingerprint.

Cite this